PROVENIR
3.1.2017 09:02:38 CET | Business Wire | Press release
Provenir, provider of real-time, risk decisioning solutions, today announced that TBI Bank, which serves consumers and businesses in Bulgaria and Romania, has chosen The Provenir Cloud for rapid risk decision-making and streamlined processing of customer applications.
Provider of consumer financing solutions, credit cards and small business lending, TBI Bank is one of the fastest growing banks in its market. Through its 65 offices and online banking services it serves over one million customers. The Bank is part of the 4Finance Group, one of Europe’s largest and fastest growing online and consumer mobile lending groups known for deploying data-driven analysis in its businesses.
The Provenir Cloud will provide TBI Bank with an efficient risk analytics and decisioning solution for faster, consistent credit and loan decisions. Provenir’s ability to integrate easily with any structured and unstructured data sources in minutes will help TBI Bank make risk decisions in seconds. TBI Bank has ambitious growth plans and at the same time will support 4Finance in a number of markets over the next 12 to 18 months. It will use The Provenir Cloud and the scalability, cost-efficiency and real-time updates it offers, as a key enabler for this growth.
“We pride ourselves on delivering a high-quality service to our customers with swift credit decisions and efficient loan application processing. The Provenir solution will help us make decisions in seconds, improve our customer experience and grow our business,” said Petr Baron, CEO of TBI.
“In the competitive market we operate in we embrace the role data-driven analytics plays in rapid credit decision-making. The technology we deploy helps us evolve our products and services and our customers’ experience. The Provenir solution will provide efficient integration to our data sources, facilitating excellent loan processing capabilities. Of particular importance to us is ease of integration and Provenir excels in this area.”
With a history of innovative product development, TBI Bank has an ongoing program of automation and digitization supporting its impressive growth. The scalable Provenir Cloud will help deliver this strategy.
“We’re delighted TBI Bank chose Provenir as they continue delivering their transformation objectives in support of their customer-centric strategy,” said Paul Thomas, Managing Director, Provenir. “Accuracy, compliance and the real-time deployment of analytics into the decisioning process all contribute to delivering a great experience for the consumer. TBI Bank recognizes the role technology plays in achieving this and we look forward to helping them achieve their goals.”
About Provenir
Provenir makes risk analytics faster and simpler for financial institutions. Our Provenir risk analytics and decisioning platform is a powerful orchestration hub that can listen to any channel, integrate with any data service and operationalize any analytic model . We help clients process more applications with greater efficiency and increase sales conversions with instant, real-time risk decisioning, serving clients across a broad range of financial verticals including consumer , commercial , cards, payments, ecommerce and auto financing. Provenir is headquartered in Parsippany, New Jersey with UK operations in London and Leeds. For more information please visit www.provenir.com .
About TBI Bank
TBI Bank is a fully licensed Bulgarian bank operating in the Bulgarian and Romanian markets as part of the 4Finance Group. The bank is specialised in Retail and SME Banking.
TBI Bank is one of the most effective, well-managed and fastest growing banks in the market. The bank is in the top 10 of profit and number one in return on assets and return on equity. TBI Bank is proud of the trust of over one million served customers. TBI Bank has 65 offices. The employees of TBI are over 1,400 people.
4finance is one of the largest and fastest growing groups in online and mobile lending for individuals. The company operates in Argentina, Armenia, Bulgaria, Georgia, Denmark, Spain, Latvia, Lithuania, Mexico, Poland, Romania, the USA, Finland, Czech Republic, Sweden, Dominican Republic, and Slovakia. The group was formed in 2008 with a vision to be a global leader offering fast and easy access to credit.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170103005027/en/
Contact:
Finn Partners
Hem Raheja
T: +44 20 3217 7060
E: hem.raheja@finnpartners.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom